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136 Poster Session-IITLR signaling and AM function, we sought to determine whether
IRAK-M was involved in PGE2-induced immunosuppression post-
BMT.
Methods: IRAK-M protein and mRNA expression were mea-
sured in AMs from control and BMT mice. Additionally, control
AMs cultured in the presence or absence of 100 nM PGE2 were an-
alyzed for IRAK-M expression. To study the role of IRAK-M post-
BMT, we transplanted either wild-type (WT) BM or IRAK-M-/-
BM into WT recipients. Levels of PGE2 were measured in AMs
five weeks post-BMT. BMT and control mice were also challenged
with P. aeruginosa infection and bacterial burden was measured in
the lung and blood 24 hours later.
Results: BMT AMs displayed elevated IRAK-M expression rela-
tive to non-transplant control AMs. Treatment of control AMs with
PGE2 upregulated IRAK-MmRNA and protein expression. Despite
overproduction of PGE2, IRAK-M-/-.WT BMT mice displayed
improved host defense against P. aeruginosa lung infection com-
pared to WT.WT BMT mice.
Conclusions: PGE2 may impair host defense against P. aerugi-
nosa in BMT AMs via upregulation IRAK-M. Strategies to limit
IRAK-M elevation post-BMT may prove efficacious in limiting in-
fections post-BMT.380
PLASMACYTOID CD1231 DENDRITIC CELL RECOVERY AND REDUCED
ACTIVATION STATE OF CIRCULATING CD81 T CELLS PREDICT SURVIVAL
AFTER UNRELATED CORD BLOOD TRANSPLANT (UCBT)
Wilfret, D.A.1, Mendizabal, A.M.2, Reese, M.1, Vinesett, R.1,
Kurtzberg, J.1, Szabolcs, P.1,3 1Duke University, Durham, NC; 2The
EMMES Corporation, Rockville, MD; 3Duke University, Durham, NC
Background: Reconstitution of adaptive immunity is critical for
long term survival following HCT. UCBT is a suitable option for
those who lack HLA-matched sibling donors. Antigen presenting
dendritic cells (DC) and lymphocytes are critical for acquiring pro-
tective immunity. Infections remain the major cause of TRM. In
the COBLT study, successful recovery of antiviral cellular immunity
was associated with a reduced rate of relapse.
Methods: Between July 2005, and December 2007, 95 children
with full donor chimerism following myeloablative conditioning
and a single cord UCBT were assessed for reconstitution of DC
andT cell subsets, B andNK cells at 3, 6, 12, 24, and 36months after
UCBT to analyze their impact on overall survival (OS).
Results: 52 and 43 children were transplanted for non-malig-
nant and malignant diseases, respectively. The median age was
2.7 years, 55 patients were male, 38 (40%) were 4/6, 39 (41%)
were 5/6 and 18 (19%) were 6/6 HLA match. The median in-
fused TNC and CD341 cell dose was 7.2  107/kg and 1.9 
105/kg, respectively. Of the 95 patients, 6 died before day 180,
11 died between day 180 and 365 [1-year survival probability
81.7% (95% CI 72.2%-88.2%)], and 8 died between day 365
and 730 [2-year survival probability 69.1% (95% CI 57.1%-
78.3%)]. In an univariate analysis of OS post-transplant, non-ma-
lignant diagnosis (HR 5 0.25, p 5 0.001), HLA match of 5/6 or
6/6 (HR 5 0.41, p 5 0.02), absolute number of CD1231 ‘‘plas-
macytoid’’ dendritic cells (pDC) .8 cells/ul (HR 5 42, p 5
0.04), %CD45RA1/CD62L1 ‘‘recent thymic emigrants’’ .13%
(HR 5 0.41, p 5 0.02), %HLA-DR1/CD81 T cells \19%
(HR 5 0.25, p 5 0.01) were each associated with a decreased
risk of death, while ‘‘myeloid’’ DC and other lymphocyte recovery
had no statistical impact. In this cohort where all studied patients
have successfully engrafted, gender, race, CMV serology, TNC,
CD341 cell dose, and TBI had no impact. In multivariate
models non-malignant disease remained a predictor for better
OS. (HR 5 0.27, p 5 0.002). Two immune parameters remained
significant predictors of survival when patient and graft specific
variables were included in multivariate analysis; abs# of
CD1231 pDC .8 cells / ul (p 5 0.05) and %HLA-DR1/
CD81 T cells \19% (p 5 0.01).
Conclusion: This is the first analysis to suggest that the absolute
number of CD1231 pDC .8 Cells /ul is an independent predictor
of survival after UCBT. Independently, lower activation state of
CD81 T cells also correlates with superior survival.Table 1. Univariate andmultivariate analysis of overall survival
(OS).
Hazard Ratio P-valueUnivariate Model
GenderFemale 1.52 0.3
Male 1.00Disease
Non-Malignant 0.25 0.001
Malignant 1.00Cell Doses
TNC / kg 1.03 0.4
CD341 / kg 1.01 0.9HLA Match
5 / 6 or 6 / 6 0.41 0.02
4 / 6 1.00Cell Type
Absolute Number of CD1231DC (pDC / ul) 0.42 0.04
CD45RA1/CD62L1 ‘‘Recent Thymic
Emigrants’’ .13%0.41 0.02%HLA-DR1/CD81 T cells\19% 0.25 0.01
Multivariate ModelDisease
Non-Malignant 0.27 0.002
Malignant 1.00HLA Match
5 / 6 or 6 / 6 0.53 0.1
4 / 6 1.00Cell Type
Absolute Number of CD1231 (pDC / ul) 0.44 0.05
HLA-DR1/CD81 T Cells\19% 0.29 0.01381
HOMEOSTATIC MECHANISMS AFFECT RECONSTITUTION OF CD41
FOXP31 REGULATORY T CELLS AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Matsuoka, K.-i., Kim, H.T., McDonough, S., Herrera, M., Cutler, C.S.,
Koreth, J., Reynolds, C., Antin, J.H., Soiffer, R.J., Ritz, J. Dana-Farber
Cancer Institute, Harvard Medical School, Boston, MA
CD41FoxP31 regulatory T cells (Treg) play a critical role in im-
mune tolerance after allogeneic HSCT but the homeostatic mecha-
nisms that affect Treg reconstitution post-HSCT have not been
identified. To address this issue we simultaneously examined pheno-
typic and functional characteristics of Treg and CD41FoxP3- con-
ventional T cells (Tcon) in peripheral blood after allogeneic HSCT
(n 5 16, median 10 months post-HSCT). Post-HSCT Treg ex-
pressed higher levels of mitotic marker Ki-67 than Tcon (median
5.2% vs 1.5%; p\0.0001) and Treg from normal donors (median
5.2% vs 2.5%; p 5 0.03). %Ki-671 Treg was inversely correlated
with peripheral CD4 count (r5 -0.86, p\0.0001). To assess survival
of Treg, we purified 4 different CD41 T cell subsets by cell sorting
(CD45RA1 Tcon, CD45RA- Tcon, CD45RA1 Treg and
CD45RA- Treg) from 4 healthy donors, 8 patients post-autologous
and 8 post-allogeneicHSCT. Each subset was cultured with or with-
out agonistic FAS antibody and apoptosis was measured using An-
nexin-V staining. Anti-FAS rapidly induced apoptosis of
CD45RA- Treg from patients (median 25.3%) while all other
Treg and Tcon (median 4.5%, p\0.0001) subsets were relatively re-
sistant to apoptosis. The degree of memory CD45RA- Treg apopto-
sis is equivalent after autologous and allogeneicHSCT, but inversely
correlated with the peripheral lymphocyte count in the patient (r 5
-0.54, p 5 0.03). The effect of lymphopenia was also evaluated by
prospectively monitoring Treg and Tcon recovery 3–24 months
post-HSCT in 46 patients who received peripheral stem cell grafts
from HLA-identical donors after myeloablative conditioning. In
27 patients with .220/ul CD4 T cells at 6 months, both Tcon and
Treg gradually increased over the subsequent 18 months. In con-
trast, in 19 patients with\220/ul CD4 T cells at 6 months, Tcon
gradually increased but Treg decreased over the subsequent 12–24
months. These results indicate that Treg reconstitution is character-
ized by increased peripheral proliferation but this is counterbalanced
by increased sensitivity to apoptosis. These characteristics are more
Poster Session-II 137evident in lymphopenic patients, suggesting that lymphopenia-
driven proliferation and apoptosis skew Treg reconstitution. This
homeostatic process does not affect the survival of other CD4 T
cell subsets, resulting in a relative deficiency of Treg post-HSCT.
Our findings provide important information for developing strate-
gies to modulate Treg and promote immune tolerance after
HSCT.382
CELLULAR IMMUNE RECONSTITUTION AND ITS IMPACT ON CLINICAL
OUTCOME IN CHILDREN WITH THALASSEMIA MAJOR UNDERGOING A
MATCHED RELATED ALLOGENEIC BONE MARROW TRANSPLANT (BMT)
Rajasekar, R., Mathews, V., Lakshmi, K.M., George, B.,
Viswabandya, A., Chandy, M., Srivastava, A. Christian Medical College,
Vellore, Tamil Nadu, India
We have prospectively analyzed cellular immune reconstitution
(IR) in pediatric patients with ß thalassemia major who underwent
myeloablative HLA matched related allogeneic BMT at our centre.
A total of 63 such consecutive patients were included in the study.
Samples from bone marrow graft and post-transplant peripheral
blood samples from recipients (day 15, 28, 45 and 2, 3, 6, 9 and 12
months) were assessed for stem cells, lymphocytes and dendritic
cell subsets. The median age of the cohort was 7 years (range: 2–
14) and there were 37 (59%) males. All patients received myeloabla-
tive conditioning regimen. Bone marrow was the graft source in
61(unprimed in 37; G-CSF primedmarrow in 24) while two patients
received PBSC. Cyclosporine and short course methotrexate was
used as GVHD prophylaxis. A CD34 cell dose above the median
value of 7.3  106/Kg had a lower incidence of bacterial (P 5
0.003) and fungal (P5 0.003) infections in the post-transplant period
and was not associated with an increased risk of GVHD.Themedian
time to engraftment was not different between these groups (17 vs.
16 days, P 5 0.531). Among cases that did develop grade II-IV
GVHD the absolute CD8 (116 vs.52 cells/ml, P5 0.012), both naı¨ve
(74 vs. 9 cells/ml, P 5 0.005) and memory counts (44 vs.21 cells/ml,
P5 0.010) were significantly higher on day 15. Only one of eight pa-
tients who eventually developed acute GVHD had evidence of acute
GVHD at this time point. Fifteen patients (24%) rejected their graft
(7 primary and 8 secondary). The day 28 NK cell count was signifi-
cantly associated with secondary graft rejection, EFS and OS when
analyzed as continuous variable in univariate analysis (P 5 0.044,
0.013 and 0.034 respectively). On a multivariate analysis, patients
with #142 NK cells/ml (median value) on day 28 had significantly
higher rejection (HR 5 11.1, P 5 0.038) and lower EFS (HR 5
16.3, P 5 0.034). Table 1 compares the characteristics of cases
with a day 28 NK cell count # the median value and those above
it. These data suggest that the stem cell dose along with patterns
of cellular IR have a significant impact on clinical outcomes such
as infection, rejection and EFS.Table 1. Comparison of low and high day 28 NK cell count
patient groups
Day 28 NK
cell count
[n (%) / median (range)]CharacteristicsLow
(# 142/ml)
n526High
(142/ml.)
n526 P-valueAge (years) 7 (2 – 14) 8 (2 – 13) 0.904
Males 15 (58) 16 (62) 1.000
Sex mismatch transplant 10 (39) 9 (35) 1.000
Lucarelli Class III 14 (54) 11 (42) 0.579
TNC (10E8/Kg) 4.2 (1.7 – 10) 4.6 (1.7 – 22.7) 0.442
ANC .500 /mm3 17 (11 – 23) 16 (13 – 20) 0.358
Acute GVHD (Grade II-IV) 3 (12) 4 (15) 1.000
Chronic GVHD 2 (9) 3 (13) 1.000
Secondary graft rejection 7 (35) 1 (4) 0.021
EFS at 3 years 64 6 10% 96 6 4% 0.006383
RAPID GENERATION OF ANTIGEN-SPECIFIC T CELLS FOR PRE-CLINICAL
AND CLINICAL APPLICATIONS USING A NOVEL MINI CELL BIOREACTOR
Brenner, L.1, Leen, A.M.1, Wilson, J.2, Heslop, H.E.1, Dotti, G.1,
Rooney, C.M.1, Vera, J.F.1 1Baylor College of Medicine, Houston, TX;
2Wilson Wolf Manufacturing, New Brighton, MN
The production of antigen-specific T cells for the reconstitution
of tumor or pathogen-specific immunity after HSCT is limited by
the time taken to produce large T cell numbers, while retaining
function and specificity. The requirements for expansion of anti-
gen-driven cytotoxic T lymphocytes (CTLs) are rigorous, and in
some cases only possible in 2 cm2 wells. Conventional cell growth
is limited by gas exchange, nutrients and waste build-up. Bioreac-
tors developed to solve these problems tend to be complex and ex-
pensive and not always conducive to antigen-specific T cell
growth. We have now explored the use of a new static mini Cell
Bioreactor (CBR); essentially a flask with a gas permeable mem-
brane base. The O2/CO2 exchange from the base allows large
heights of media above the cells reducing nutrient limitations,
waste build-up, and manipulation. We tested two different sizes
of CBR, 10 cm2 and 100 cm2 that hold a maximum of 40mL
and 2000L of media, respectively. We were able to generate and
expand Epstein-Barr virus antigen-specific cytotoxic T lympho-
cytes (EBV-CTLs) from normal donors by coculturing antigen
presenting cells (APC) (1.4E105 x cm2) with established EBV
CTL (4.3E103 x cm2) at an optimized cell density and stimulator:
responder ratio (32:1). These culture conditions produced higher
cell yields in the CBR vs. conventional method (42.5 fold 614.8
vs 3.4 fold 61.2 within 7 days) without media change, and manip-
ulation restricted to cytokine addition every 3–4 days. A single
100cm2 bioreactor could produce up to 800E106 antigen-specific
T cells from a starting 10E106 PBMC, which would have re-
quired approximately 320 wells in 24 well plates under standard
culture conditions. The CD4:CD8 T cell ratio and phenotype
was similar to those expanded using the conventional method
(CD27 48% vs 52.4%, CD28 65.2% vs 62.2%, CD62L 53.15%
vs 54.5%, CD45RO 58.1% vs 55.7%, and CD45RA 51.1% vs
54.9%). Antigen specificity, as evaluated by tetramer analysis,
and IFN-g ELIspot and chromium release assays revealed no sig-
nificant differences. In summary, we have successfully utilized the
new mini Cell Bioreactor technology to induce optimal in vitro ex-
pansion of virus-specific CTLs with minimal handling. This new
cell culture technology can readily be extended it to others cells
products in order to facilitate the application of cell therapy ap-
proaches. This work was supported in part by a Production Assis-
tance for Cellular Therapies PACT (NO1HB37163–C001) from
NHLBI384
ABSOLUTE LYMPHOCYTE COUNT KINETICS MAY PREDICT THE CLINICAL
OUTCOME AFTER RELATED ALLOGENEIC PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION WITH A BUSULFAN-BASED REDUCED-INTEN-
SITY CONDITIONING REGIMEN
Yakushijin, K., Fukuda, T., Saito, B., Kurosawa, S., Asakura, Y.,
Azuma, T., Kim, S.-W., Mori, S.-i., Tanosaki, R., Heike, Y.,
Takaue, Y. National Cancer Center Hospital, Tokyo, Japan
In autologous hematopoietic stem cell transplantation (HSCT),
early recovery of the absolute lymphocyte count (ALC/mm3) is
known to be associated with better overall survival (OS). Although
similar observations have been reported after myeloablative alloge-
neicHSCT, little is known in the setting of RIST. Previously, we ob-
served that donor T-cell chimerism at 1 month after busulfan-based
RIST may predict the clinical outcome (Saito et al., BBMT, 2008).
To further extend this analysis, we retrospectively reviewed themed-
ical records of 88 patients (median age, 54 y (29–68)) who underwent
busulfan-based RIST at our hospital between 2000 and 2007. The
conditioning regimen consisted of busulfan (oral 8 mg/kg or iv 6.4
mg/kg) and fludarabine (180 mg/m2, n 5 41) or cladribine (0.66
mg/kg, n 5 47), and one patient received 2Gy TBI. The diagnosis
included ML (n 5 37), AML/MDS (n 5 38), and other (n 5 13).
All patients received G-CSF-mobilized PBSCs from related donors
